Nicotine salt with meta-salicylic acid and applications therein
Inventors
Myers, Daniel J. • Cassella, James
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-11458130-B2
Publication Date
2022-10-04
Expiration Date
Abstract
The present disclosure relates generally to the field of nicotine delivery. The disclosure teaches a nicotine meta-salicylate. More specifically, the disclosure teaches a condensation nicotine aerosol where nicotine meta-salicylate is vaporized. This disclosure relates to aerosol nicotine delivery devices. The delivery devices can be activated by actuation mechanisms to vaporize thin films comprising a nicotine meta-salicylate. More particularly, this disclosure relates to thin films of nicotine salt with meta salicylic acid for the treatment of nicotine craving and for effecting smoking cessation.
Core Innovation
The invention provides a drug delivery and drug cessation system that includes a portable vapor-based drug delivery device and a portable control device. The portable drug delivery device includes a drug payload, a dosage delivery device, and a first wireless transceiver, and it delivers a drug to a body of a user based on instructions received from the portable control device through wireless communication between the two portable devices.
The portable drug delivery device further comprises a breath actuator and a lockout unit. The breath actuator is configured to cause the dosage delivery device to deliver a supplemental dose of the drug from the drug payload based on a determination that the user has inhaled from the portable drug delivery device, and the lockout unit prevents the breath actuator from causing supplemental dosing during a predetermined period when the supplemental dose would exceed a predetermined maximum dose for that period.
The disclosed system also enables supplemental delivery without receiving instructions from the portable control device and contrary to preset dosage schedules, while still enforcing the maximum-dose constraint through the lockout unit. The document further describes dose counting/logging, tapering or dose reduction therapy concepts, and networked communication to a healthcare professional for drug dosage prescriptions.
The disclosed implementation includes examples centered on condensation nicotine aerosol generation using nicotine meta-salicylate, including vaporizing nicotine meta-salicylate thin films on heat-conductive substrates to form inhalable aerosols with controlled particle size and high purity with low thermal degradation.
Claims Coverage
The provided claim coverage centers on wireless, portable vapor-based drug delivery and supplemental inhalation-triggered dosing constrained by a maximum-dose lockout. The partial content identifies one independent claim with four inventive features.
Wireless portable vapor-based delivery with control instructions
A portable drug delivery device configured to deliver a drug to a body of a user based on instructions received from a portable control device via wireless communication, where the portable drug delivery device is a vapor-based drug delivery device and includes a drug payload, a dosage delivery device, and a first wireless transceiver while the portable control device includes a second wireless transceiver.
Inhalation-triggered supplemental dosing
A breath actuator configured to cause the dosage delivery device to deliver a supplemental dose of the drug from the drug payload, based on a determination that the user has inhaled from the portable drug delivery device.
Maximum-dose lockout for supplemental dosing
A lockout unit configured to prevent the breath actuator from causing the dosage delivery device to deliver the supplemental dose of the drug during a predetermined period based on a determination that the supplemental dose would exceed a predetermined maximum dose of the drug for the predetermined period.
Supplemental dosing without control-device instructions contrary to preset schedules
The breath actuator is configured to cause the dosage delivery device to deliver the supplemental dose of the drug from the drug payload, based on a determination that the user has inhaled from the portable drug delivery device, without receiving the instructions from the portable control device and contrary to any preset dosage schedules.
The inventive features combine wireless control of a portable vapor-based drug delivery device with inhalation-triggered supplemental dosing and a lockout unit that enforces a predetermined maximum dose.
Stated Advantages
High purity and low thermal degradation for vaporized nicotine meta-salicylate condensation aerosol, including low thermal degradation products.
Controlled particle size of inhalable aerosol generated from vaporized nicotine meta-salicylate thin films.
Improved stability of nicotine meta-salicylate compared with nicotine o-salicylate, as described in experimental examples.
Prevention of supplemental dosing when it would exceed a predetermined maximum dose during a predetermined period.
Recording and use of delivery history, including communication with a healthcare professional for drug dosage prescriptions.
Documented Applications
Nicotine delivery and drug cessation control using condensation nicotine aerosol generated from nicotine meta-salicylate, including thin-film vaporization on heat-conductive substrates.
Drug cessation therapy concepts using tapering or dose reduction via portable control and vapor-based delivery, including dose counting/logging and dose constraints.
A system architecture for supplemental dosing triggered by user inhalation while preventing supplemental dosing during predetermined periods when a maximum dose would be exceeded.
Healthcare professional involvement through network communication of delivery history and receipt of drug dosage prescriptions.
Interested in licensing this patent?